{"id":114692,"date":"2006-06-19T16:07:00","date_gmt":"2006-06-19T20:07:00","guid":{"rendered":"https:\/\/www.send2press.com\/wire\/epeius-biotechnologies-corporation-receives-400000-grant-to-support-gene-therapy-trials-for-pancreatic-cancer\/"},"modified":"2006-06-19T16:07:00","modified_gmt":"2006-06-19T20:07:00","slug":"epeius-biotechnologies-corporation-receives-400000-grant-to-support-gene-therapy-trials-for-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/www.send2press.com\/wire\/epeius-biotechnologies-corporation-receives-400000-grant-to-support-gene-therapy-trials-for-pancreatic-cancer\/","title":{"rendered":"Epeius Biotechnologies Corporation Receives $400,000 Grant to Support Gene Therapy Trials for Pancreatic Cancer"},"content":{"rendered":"<p class=\"s2pred\"><strong>NEWS SOURCE: Epeius Biotechnologies Corporation<\/strong><\/p>\n<p>SAN MARINO, CA &#8211; June 19 (SEND2PRESS NEWSWIRE) &#8212; Epeius Biotechnologies Corporation announced today that the Company has been awarded a $400,000 grant by the Lazarex Cancer Foundation to expand and support ongoing cancer gene therapy clinical trials for advanced and metastatic pancreatic cancer. <\/p>\n<p> <img decoding=\"async\" src=\"\/mediaboom\/0606-epeius.jpg\" align=\"left\" hspace=\"20\" lowsrc=\"https:\/\/www.send2press.com\/wire\/images\/0606-epeius.jpg\" \/>Rexin-G(TM) is the world&#8217;s first targeted injectable gene therapy vector to be approved for use in clinical trials in the USA and abroad. When injected intravenously, Rexin-G(TM) seeks out and destroys metastatic cancer, without the systemic toxicity generally associated with chemotherapy. <\/p>\n<p> Rexin-G recently gained Orphan Drug status as an effective treatment for pancreatic cancer in the United States, and is currently available in clinical trials in Rochester MN. <\/p>\n<p> In a statement to the press, Ms. Dana Dornsife, President of the Lazarex Cancer Foundation said: &#8220;We are pleased to provide Epeius Biotechnologies Corporation the funds needed to expedite the development of such promising genetic medicines, which &#8211; by improving both the survival and the quality of life &#8211; provide cancer patients with more quality time.&#8221;<\/p>\n<p> More information: <a href=\"http:\/\/www.epeiusbiotech.com\" target=\"_new\" rel=\"noopener\">http:\/\/www.epeiusbiotech.com<\/a><\/p>\n<p>News issued by: Epeius Biotechnologies Corporation<\/p>\n<p> # # # <\/p>\n<p><small>Original Story ID:  (1748) :: 2006-06-0619-001<\/small><\/p>\n<p><small>Original Keywords: Rexin-G, Lazarex Cancer Foundation, clinical trials in the USA and abroad, destroys metastatic cancer, chemotherapy, Dana Dornsife, Dr. Erlinda M. Gordon, Dr. Frederick L. Hall, California, california news Epeius Biotechnologies Corporation   <\/small><\/p>\n<p class=\"s2pred\"><strong>NEWS SOURCE: Epeius Biotechnologies Corporation<\/strong> | Published: 2006-06-19 16:07:00<\/p>\n","protected":false},"excerpt":{"rendered":"<p>SAN MARINO, CA &#8211; June 19 (SEND2PRESS NEWSWIRE) &#8212; Epeius Biotechnologies Corporation announced today that the Company has been awarded a $400,000 grant by the Lazarex Cancer Foundation to expand and support ongoing cancer gene therapy clinical trials for advanced and metastatic pancreatic cancer.<\/p>\n","protected":false},"author":9780,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"singles-wide.php","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[19937],"tags":[],"class_list":["post-114692","post","type-post","status-publish","format-standard","hentry","category-press-releases-archive","has-post-title","has-post-date","no-post-category","no-post-tag","no-post-comment","has-post-author"],"acf":[],"views":576,"_links":{"self":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/114692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/users\/9780"}],"replies":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/comments?post=114692"}],"version-history":[{"count":0,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/114692\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media?parent=114692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/categories?post=114692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/tags?post=114692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}